Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Forecast: Value Set To Climb From $2.28 Billion To $3.76 Billion
The temperature-stable messenger ribonucleic acid (mrna) vial market size has experienced rapid expansion over recent years. It is anticipated to grow from $2.01 billion in 2025 to $2.28 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.6%. Factors contributing to its historical growth include the broadening of mrna vaccine research, a rise in investment within lipid nanoparticle technologies, the expansion of worldwide immunization efforts, the challenges posed by cold-chain logistics that necessitated alternative solutions, and the initial implementation of stabilized mrna delivery systems.
The market for temperature-stable messenger ribonucleic acid (mRNA) vials is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $3.77 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.3%. Factors contributing to this growth during the forecast period include a heightened demand for advanced mRNA therapeutics, a greater emphasis on worldwide vaccine availability, the expansion of decentralized healthcare systems, increased investments in biologics that can withstand varying temperatures, and a rise in regulatory approvals for mRNA-based innovations. Key trends observed throughout this period encompass the accelerated development of thermostable mRNA formulations, a growing preference for lyophilized mRNA vials, an increasing need for storage solutions that do not require a cold chain, the broadening of global mRNA distribution initiatives, and an intensified focus on the integrity and stability of packaging.
Get A Free Sample Report With In-Depth Market Insights:
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Growth Factors Behind Sustained Expansion
The expanding involvement in worldwide immunization initiatives is anticipated to fuel the expansion of the temperature-stable messenger ribonucleic acid (mRNA) vial market in the coming period. A vaccine is a material engineered to stimulate the body’s immune system, assisting it in developing defense against a specific illness. This surge in global vaccine uptake stems from international cooperation, where synchronized actions among nations guarantee broader availability and fair distribution of vaccines. Temperature-stable mRNA vials facilitate global vaccination by permitting simpler storage, transit, and dissemination across various territories, eliminating the need for intricate cold chain infrastructure, thus ensuring greater reach and continuous immunization coverage globally. For example, data from October 2025, provided by Gavi, a US-based international organization that provides vaccines to children in developing countries, indicated that DTP3 vaccine coverage in Gavi-supported lower-income countries rose to 82%, an increase from 80% in 2023, approaching levels seen before the pandemic. Consequently, the growing involvement in global vaccination efforts is propelling the expansion of the temperature-stable messenger ribonucleic acid (mRNA) vial market.
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Segment Analysis Spotlighting Growth Areas
The temperature-stable messenger ribonucleic acid (mrna) vial market covered in this report is segmented –
1) By Product Type: Lipid Nanoparticle Formulations, Polymer-Based Formulations, Lyophilized Messenger Ribonucleic Acid (mRNA) Vials, Other Product Types
2) By Distribution Channel: Direct Sales, Distributors, Online Sales, Other Distribution Channels
3) By Application: Vaccines, Therapeutics, Research, Other Applications
4) By End User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users
Subsegments:
1) By Lipid Nanoparticle Formulations: Cationic Lipid Nanoparticles, Ionizable Lipid Nanoparticles, Neutral Lipid Nanoparticles
2) By Polymer-Based Formulations: Polyethylene Glycol-Based Formulations, Polymeric Micelles, Dendrimer-Based Formulations
3) By Lyophilized Messenger Ribonucleic Acid Vials: Single-Dose Vials, Multi-Dose Vials
4) By Others Product Types: Peptide-Based Formulations, Protein-Based Formulations, Hybrid Formulations
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Industry Trends Fueling Future Revenue Growth
Leading companies within the temperature-stable messenger ribonucleic acid (mRNA) vial market are concentrating on formulating novel approaches, including technology transfer frameworks, to boost manufacturing effectiveness, enlarge global production capacity, and enhance vaccine access in low- and middle-income regions. Technology transfer models describe processes for transmitting knowledge, skills, and manufacturing techniques from one entity to another, facilitating local manufacturing and wider dissemination. For example, SCHOTT Pharma, a pharmaceutical packaging company headquartered in Germany, unveiled its EVERIC freeze vials in January 2024. These EVERIC freeze vials are designed to endure temperatures down to -80°C, making them ideal for vaccines and medications such as mRNA and gene therapy treatments applied to infectious diseases, cancer, and central nervous system ailments. Their optimized strength design reduces the likelihood of breakage, thereby preventing the spoilage of vital medications and expensive operational delays.
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the temperature-stable messenger ribonucleic acid (mrna) vial market are Arcturus Therapeutics Holdings Inc., CureVac AG, Sanofi S.A., Lonza Group AG, Gerresheimer AG, Stevanato Group, Schott AG, CSafe Global, Gennova Biopharmaceuticals Ltd., TTP Group, Peli BioThermal LLC, SiO2 Materials Science, Shijiazhuang Xinfuda Medical Packaging, Vaxess Technologies, Ethris, Lyophilization Techniques, 20Med Therapeutics BV, EnsiliTech, HDT Bio Corp., Emervax.
View The Full Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Report:
Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the temperature-stable messenger ribonucleic acid (mRNA) vial market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the temperature-stable messenger ribonucleic acid (mrna) vial market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
